Anzeige
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PM28 | ISIN: US3596161097 | Ticker-Symbol:
NASDAQ
24.04.25
21:59 Uhr
3,500 US-Dollar
-0,080
-2,23 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
FULCRUM THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
FULCRUM THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur FULCRUM THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiPre-market Movers: Gelteq, MicroCloud Hologram, SHF Holdings, Orchestra Biomed, Fulcrum Therapeutics313BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.25 A.M. ET).In the Green Gelteq Ltd (GELS) is up over 445% at $5.05. MicroCloud...
► Artikel lesen
11.04.Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)106CAMBRIDGE, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives...
► Artikel lesen
FULCRUM THERAPEUTICS Aktie jetzt für 0€ handeln
05.03.Fulcrum Therapeutics, MyoKardia end agreement on cardiomyopathy treatments1
04.03.Fulcrum Therapeutics, Inc. - 8-K, Current Report-
25.02.Fulcrum Therapeutics GAAP EPS of -$0.31 misses by $0.033
25.02.Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024723? On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025 and the 20 mg dose cohort by the end of 2025 ? ? Ended 2024 with...
► Artikel lesen
25.02.Fulcrum Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
25.02.Fulcrum Therapeutics, Inc. - 10-K, Annual Report-
25.02.Fulcrum Therapeutics, Inc. - 8-K, Current Report-
24.02.Fulcrum Therapeutics Q4 2024 Earnings Preview2
07.02.Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)123CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives...
► Artikel lesen
13.01.Fulcrum Therapeutics, Inc. - 8-K, Current Report-
23.12.24Fulcrum Therapeutics, Inc. - 8-K, Current Report-
14.11.24Expert Ratings For Fulcrum Therapeutics7
13.11.24Fulcrum Therapeutics, Inc. - 10-Q, Quarterly Report-
12.11.24Fulcrum Therapeutics, Inc. - 8-K, Current Report-
12.11.24Earnings Preview: Fulcrum Therapeutics2
12.11.24Fulcrum Therapeutics' Earnings Outlook1
11.10.24Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)309CAMBRIDGE, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives...
► Artikel lesen
13.09.24Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)280CAMBRIDGE, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives...
► Artikel lesen
Seite:  Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1